Robert W. Baird Issues Positive Forecast for Denali Therapeutics (NASDAQ:DNLI) Stock Price

Denali Therapeutics (NASDAQ:DNLI) had its price objective boosted by Robert W. Baird from $32.00 to $34.00 in a research note issued to investors on Tuesday morning,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Other equities analysts have also issued reports about the company. HC Wainwright raised their price target on Denali Therapeutics from $32.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. UBS Group began coverage on Denali Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a report on Wednesday, January 21st. Jefferies Financial Group reaffirmed a “buy” rating and issued a $40.00 price target on shares of Denali Therapeutics in a report on Monday, March 2nd. Finally, Stifel Nicolaus raised their price target on Denali Therapeutics from $34.00 to $41.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $35.00.

Denali Therapeutics Stock Performance

NASDAQ:DNLI opened at $19.41 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.16 and a quick ratio of 9.16. The business has a fifty day simple moving average of $20.43 and a two-hundred day simple moving average of $18.17. Denali Therapeutics has a 1 year low of $10.80 and a 1 year high of $23.77. The company has a market capitalization of $3.08 billion, a P/E ratio of -6.54 and a beta of 1.10.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.02. During the same period in the previous year, the company earned ($0.67) earnings per share. On average, analysts expect that Denali Therapeutics will post -2.71 earnings per share for the current year.

Institutional Investors Weigh In On Denali Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Foresite Capital Management VI LLC bought a new stake in Denali Therapeutics during the third quarter worth about $14,520,000. AlphaQuest LLC lifted its stake in Denali Therapeutics by 224.1% during the third quarter. AlphaQuest LLC now owns 74,422 shares of the company’s stock worth $1,081,000 after purchasing an additional 51,458 shares during the last quarter. Aberdeen Group plc lifted its stake in Denali Therapeutics by 23.4% during the third quarter. Aberdeen Group plc now owns 1,113,586 shares of the company’s stock worth $16,169,000 after purchasing an additional 210,835 shares during the last quarter. Principal Financial Group Inc. lifted its stake in Denali Therapeutics by 18.5% during the third quarter. Principal Financial Group Inc. now owns 1,271,190 shares of the company’s stock worth $18,458,000 after purchasing an additional 198,207 shares during the last quarter. Finally, Capricorn Fund Managers Ltd bought a new stake in Denali Therapeutics during the fourth quarter worth about $1,027,000. Institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.